Association of Antithrombin Activity With Enoxaparin Responsiveness and Venous Thromboembolism in Trauma Patients
This cohort study of patients from a level 1 trauma center examines the association of changes in antithrombin activity over time with anti –factor Xa levels in response to enoxaparin prophylaxis and with risk of trauma-related venous thromboembolism. (Source: JAMA Surgery)
Source: JAMA Surgery - June 22, 2022 Category: Sports Medicine Source Type: research

A Personalized Approach to Prevention of Venous Thromboembolism
This article adds to recent literature that recognizes key pitfalls in a universal approach to prevention of trauma-related VTE in contrast to a personalized approach to identify anticoagulant resistance and/or nonresponsiveness to optimize therapy. (Source: JAMA Surgery)
Source: JAMA Surgery - June 22, 2022 Category: Sports Medicine Source Type: research

Bemiparin vs enoxaparin in the prevention of thrombosis in microvascular head and neck reconstruction
This study aims to compare the use of Bemiparin vs Enoxaparin in patients undergoing microvascular head and neck reconstruction, analyzing the incidence of flap thrombotic complications and local bleeding that could compromise the flap survival. This is an observational study on a group of 204 patients who underwent a microvascular flap for head and neck reconstruction at the Oral and Maxillofacial Surgery Department of Ramon y Cajal Hospital in Madrid, Spain. A group of 67 patients was treated according to a protocol for postoperative prophylaxis of thromboembolism with Bemiparin, which was compared with data collected re...
Source: Journal of Plastic, Reconstructive and Aesthetic Surgery - June 20, 2022 Category: Cosmetic Surgery Authors: Kora Sag üillo, Francisco Pérez-Flecha, Fernando Almeida, Manuel Picón, Julio Acero Tags: Correspondence and Communications Source Type: research

Standard Fixed Enoxaparin Dosing for Venous Thromboembolism Prophylaxis Leads to Low Peak Anti-Factor Xa Levels in Both Head and Neck and Breast Free Flap Patients
Conclusion Standard fixed enoxaparin dosing for postoperative VTE prophylaxis does not achieve target afXa levels for the majority of our free flap patients. H&N patients appear to be a particularly high-risk group that may require a more personalized and aggressive approach. Total body weight is the sole negative predictor of afXa level, supporting a role for weight-based enoxaparin dosing. [...] Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USAArticle in Thieme eJournals: Table of contents  |  Abstract  |  Full text (Source: Journal of Reconstructive Microsurgery)
Source: Journal of Reconstructive Microsurgery - June 17, 2022 Category: Surgery Authors: Ambani, Shoshana W. Bengur, Fuat Baris Varelas, Lee J. Nguyen, Vu T. Cruz, Carolyn De La Acarturk, Tahsin Oguz Manders, Ernest K. Kubik, Mark W. Sridharan, Shaum Gimbel, Michael L. Solari, Mario G. Tags: Original Article Source Type: research

Pharmacokinetic, Hemostatic, and Anticancer Properties of a Low-Anticoagulant Bovine Heparin
TH Open. 2022 May 26;6(2):e114-e123. doi: 10.1055/s-0042-1745743. eCollection 2022 Apr.ABSTRACTHeparin is a centennial anticoagulant drug broadly employed for treatment and prophylaxis of thromboembolic conditions. Although unfractionated heparin (UFH) has already been shown to have remarkable pharmacological potential for treating a variety of diseases unrelated with thromboembolism, including cancer, atherosclerosis, inflammation, and virus infections, its high anticoagulant potency makes the doses necessary to exert non-hemostatic effects unsafe due to an elevated bleeding risk. Our group recently developed a new low-an...
Source: Atherosclerosis - June 16, 2022 Category: Cardiology Authors: Roberto P Santos Ana M F Tovar Marcos R Oliveira Adriana A Piquet Nina V Capill é Stephan N M C G Oliveira Ana H Correia Jos é N Farias Eduardo Vilanova Paulo A S Mour ão Source Type: research

Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study
CONCLUSIONS: In RIETECAT, in patients with cancer and VTE receiving full-dose enoxaparin or dalteparin or tinzaparin, no statistically significant differences were observed regarding effectiveness and safety outcomes over a 6-month period.PMID:35664535 | PMC:PMC9164243 | DOI:10.1002/rth2.12736 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - June 6, 2022 Category: Hematology Authors: Javier Trujillo-Santos Dominique Farge-Bancel Jos é María Pedrajas Covadonga G ómez-Cuervo Aitor Ballaz Andrei Braester Isabelle Mah é Aurora Villalobos Jos é Antonio Porras Manuel Monreal RIETE Investigators Source Type: research

Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study
CONCLUSIONS: In RIETECAT, in patients with cancer and VTE receiving full-dose enoxaparin or dalteparin or tinzaparin, no statistically significant differences were observed regarding effectiveness and safety outcomes over a 6-month period.PMID:35664535 | PMC:PMC9164243 | DOI:10.1002/rth2.12736 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - June 6, 2022 Category: Hematology Authors: Javier Trujillo-Santos Dominique Farge-Bancel Jos é María Pedrajas Covadonga G ómez-Cuervo Aitor Ballaz Andrei Braester Isabelle Mah é Aurora Villalobos Jos é Antonio Porras Manuel Monreal RIETE Investigators Source Type: research

An Open-Label, Single-Arm, Pilot Intervention Study to Assess the Efficacy and Safety of Apixaban in Heparin-Induced Thrombocytopenia
This article is protected by copyright. All rights reserved.PMID:35656855 | DOI:10.1002/jcph.2096 (Source: The Journal of Clinical Pharmacology)
Source: The Journal of Clinical Pharmacology - June 3, 2022 Category: Drugs & Pharmacology Authors: Maryam Farasatinasab Saeedeh Baloochzehi Omid Moradi Moghamddam Nafiseh Ansarinejad Mahmonir Mohammadi Somayyeh Nasiripour Source Type: research

An Open-Label, Single-Arm, Pilot Intervention Study to Assess the Efficacy and Safety of Apixaban in Heparin-Induced Thrombocytopenia
This article is protected by copyright. All rights reserved.PMID:35656855 | DOI:10.1002/jcph.2096 (Source: The Journal of Clinical Pharmacology)
Source: The Journal of Clinical Pharmacology - June 3, 2022 Category: Drugs & Pharmacology Authors: Maryam Farasatinasab Saeedeh Baloochzehi Omid Moradi Moghamddam Nafiseh Ansarinejad Mahmonir Mohammadi Somayyeh Nasiripour Source Type: research

An Open-Label, Single-Arm, Pilot Intervention Study to Assess the Efficacy and Safety of Apixaban in Heparin-Induced Thrombocytopenia
This article is protected by copyright. All rights reserved.PMID:35656855 | DOI:10.1002/jcph.2096 (Source: The Journal of Clinical Pharmacology)
Source: The Journal of Clinical Pharmacology - June 3, 2022 Category: Drugs & Pharmacology Authors: Maryam Farasatinasab Saeedeh Baloochzehi Omid Moradi Moghamddam Nafiseh Ansarinejad Mahmonir Mohammadi Somayyeh Nasiripour Source Type: research

Special Considerations for Women of Reproductive Age on Anticoagulation
AbstractAnticoagulation poses unique challenges for women of reproductive age. Clinicians prescribing anticoagulants must counsel patients on issues ranging from menstruation and the possibility of developing a hemorrhagic ovarian cyst to teratogenic risks and safety with breastfeeding. Abnormal uterine bleeding affects up to 70% of young women who are treated with anticoagulation. As such, thoughtful clinical guidance is required to avoid having young women who are troubled by their menses, dose reduce, or prematurely discontinue their anticoagulation, leaving them at increased risk of recurrent thrombosis. Informed by a ...
Source: Journal of General Internal Medicine - May 31, 2022 Category: Internal Medicine Source Type: research

The mechanism by which enoxaparin sodium –high-viscosity bone cement reduces thrombosis by regulating CD40 expression in endothelial cells
PMMA bone cement leads to the development of local thrombi. Our study found that ES-PMMA bone cement, a novel material, can reduce local thrombosis. We used a simple and reproducible animal model to confirm th... (Source: BMC Musculoskeletal Disorders)
Source: BMC Musculoskeletal Disorders - May 30, 2022 Category: Orthopaedics Authors: Linchao Sang, Kangning Hao, Luobin Ding, Xiaoyu Shen, Hui Sun, Dehao Fu and Xiangbei Qi Tags: Research Source Type: research

Therapeutic anticoagulation to prevent thrombosis, coagulopathy, and mortality in severe COVID-19: The Swiss COVID-HEP randomized clinical trial
CONCLUSIONS: Among patients with severe COVID-19 treated with corticosteroids and with exclusion of pulmonary embolism at hospital admission for most, risks of mortality, thrombotic outcomes, and DIC were low at 30 days. The lack of benefit of therapeutic anticoagulation was too imprecise for definite conclusions.PMID:35599701 | PMC:PMC9116142 | DOI:10.1002/rth2.12712 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - May 23, 2022 Category: Hematology Authors: Marc Blondon Sara Cereghetti J érôme Pugin Christophe Marti Pauline Darbellay Farhoumand Jean-Luc Reny Alexandra Calmy Christophe Combescure Lucia Mazzolai Olivier Pantet Zied Ltaief Marie M éan Sara Manzocchi Besson S éverin Jeanneret Hans Stricker H Source Type: research

Therapeutic anticoagulation to prevent thrombosis, coagulopathy, and mortality in severe COVID-19: The Swiss COVID-HEP randomized clinical trial
CONCLUSIONS: Among patients with severe COVID-19 treated with corticosteroids and with exclusion of pulmonary embolism at hospital admission for most, risks of mortality, thrombotic outcomes, and DIC were low at 30 days. The lack of benefit of therapeutic anticoagulation was too imprecise for definite conclusions.PMID:35599701 | PMC:PMC9116142 | DOI:10.1002/rth2.12712 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - May 23, 2022 Category: Hematology Authors: Marc Blondon Sara Cereghetti J érôme Pugin Christophe Marti Pauline Darbellay Farhoumand Jean-Luc Reny Alexandra Calmy Christophe Combescure Lucia Mazzolai Olivier Pantet Zied Ltaief Marie M éan Sara Manzocchi Besson S éverin Jeanneret Hans Stricker H Source Type: research

Drug-Aggravated Bullous Pemphigoid in a 47-year-old Asian Woman - A Case Report
CONCLUSION: This case report was done with the purpose of presenting an exemplary case of bullous pemphigoid aggravated by the application of neem oil and emphasizing the inappropriate use of folk medicine in an autoimmune disease like bullous pemphigoid.PMID:35593331 | DOI:10.2174/1574886317666220518091554 (Source: Current Drug Safety)
Source: Current Drug Safety - May 20, 2022 Category: Drugs & Pharmacology Authors: Divyajayashree N Haritha H Senthilvel N Sam Johnson Udaya Chander J Source Type: research